Crinetics Pharmaceuticals, Inc. (CRNX) [Rocket]

In millions, except per share items	Jun-30-23	Jun-05-23	Mar-31-23	Dec-05-22	Sep-30-22	Sep-05-22	Jun-30-22	Jun-05-22
	10-Q	8-K	10-Q	8-K	10-Q	8-K	10-Q	8-K
Total revenues			41.3		37.0		3.6
Revenue growth			1218.3%
Cost of goods sold			48.3		43.5		0.0
Gross profit			-7.0		4.0		3.6
Gross margin			-16.9%		100.0%		100.0%
Selling, general and administrative [+]			149.3		156.3		140.2
Sales and marketing			138.1		124.4		108.2
Other operating expenses			17.4		19.9		-0.8
EBITDA [+]			-172.9		-147.4		-134.9
EBITDA growth			45.0%		54.1%		54.7%
EBITDA margin			-418.9%		-402.3%		-3778.9%
Depreciation and amortization			0.7		0.9		0.9
EBIT [+]			-173.7		-148.3		-135.8
EBIT growth			44.5%		53.4%		54.2%
EBIT margin			-420.8%		-404.3%		-3804.8%
Interest income			4.3		1.8		1.0
Interest income			4.3		2.5		1.0
Other income (expense), net			39.1		40.6		-0.8
Pre-tax income			-130.3		-107.3		-135.6
Income taxes			0.0		0.0		0.0
Tax rate			0.0%		0.0%		0.0%
Net income			-130.3		-107.3		-135.6
Net margin			-315.7%		-289.9%		-3799.6%

Basic EPS [+]			($2.43)		($2.23)		($3.07)
Growth			15.7%		9.7%		14.9%
Diluted EPS [+]			($2.43)		($2.23)		($3.07)
Growth			15.7%		9.7%		14.9%

Shares outstanding (basic) [+]			53.5		48.1		44.2
Growth			32.5%		38.6%		32.7%
Shares outstanding (diluted) [+]			53.5		48.1		44.2
Growth			32.5%		38.6%		32.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.